Seizures in oligodendroglial tumors

Area of Science:

• Neuro-oncology
• Epileptology
• Molecular diagnostics

Background:

• Epilepsy affects over 70-90% of oligodendroglial tumors.
• Early epilepsy can indicate favorable long-term survival.
• IDH1 mutations and altered glutamate/GABA metabolism are implicated in glioma-associated epilepsy.

Purpose of the Study:

• To review epilepsy in oligodendrogliomas.
• To discuss treatment efficacy and challenges.
• To highlight pharmacoresistance and toxicities.

Main Methods:

• Literature review of oligodendroglioma and epilepsy.
• Analysis of treatment outcomes (surgery, radiotherapy, chemotherapy).
• Evaluation of anticonvulsant therapies and resistance.

Main Results:

• Seizure freedom achieved in ~66% post-surgery/radiotherapy.
• Chemotherapy reduces seizures in ~50%.
• 40% exhibit pharmacoresistance, even with polytherapy.

Conclusions:

• Levetiracetam and valproic acid are evidence-based for partial epilepsies in brain tumors.
• Pharmacoresistance is a significant issue in oligodendroglioma-associated epilepsy.
• Anticonvulsant toxicities (cognitive, bone marrow, skin) are concerns, exacerbated by prior treatments.